The ill-fated Light trial, which was supposed to examine the cardiovascular outcomes of the weight loss drug Contrave, a combination of naltrexone and bupropion marketed by Orexigen and Takeda, came to a spectacular halt today. The action was probably inevitable given the extreme controversy generated earlier this year when it became known that Orexigen had widely disseminated results from an early interim analysis of the study.

The news about the trial was announced in a press release from the companies and a press release from the Cleveland Clinic, the home institution of Steve Nissen, the trial’s chairman.

…

Click here to read the full post on Forbes.

Previous Coverage:

• Orexigen Released Interim Data Without Approval Of Trial Leaders
• Takeda Disagrees With Orexigen Over Data Disclosure
• Orexigen Released Interim Data Without Approval Of Trial Leaders

Steven Nissen (AP Photo/Judi Bottoni)